Subjective well-being in early-phase schizophrenia patients using long-acting injectable vs. oral antipsychotic drugs: data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST)

Saved in:
Bibliographic Details
Main Authors: Anna-Theresa Schulze, Timo Schurr, Fabienne Post, Beatrice Frajo-Apor, Covadonga M. Díaz-Caneja, Walter Wolfgang Fleischhacker, Michael Davidson, Alex Hofer
Format: Article
Language:English
Published: Cambridge University Press
Series:European Psychiatry
Subjects:
Online Access:https://www.cambridge.org/core/product/identifier/S0924933825100862/type/journal_article
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849330257921835008
author Anna-Theresa Schulze
Timo Schurr
Fabienne Post
Beatrice Frajo-Apor
Covadonga M. Díaz-Caneja
Walter Wolfgang Fleischhacker
Michael Davidson
Alex Hofer
author_facet Anna-Theresa Schulze
Timo Schurr
Fabienne Post
Beatrice Frajo-Apor
Covadonga M. Díaz-Caneja
Walter Wolfgang Fleischhacker
Michael Davidson
Alex Hofer
author_sort Anna-Theresa Schulze
collection DOAJ
format Article
id doaj-art-d23106c2bcce4ac68f6be6b5a1019c71
institution Kabale University
issn 0924-9338
1778-3585
language English
publisher Cambridge University Press
record_format Article
series European Psychiatry
spelling doaj-art-d23106c2bcce4ac68f6be6b5a1019c712025-08-20T03:46:58ZengCambridge University PressEuropean Psychiatry0924-93381778-358513010.1192/j.eurpsy.2025.10086Subjective well-being in early-phase schizophrenia patients using long-acting injectable vs. oral antipsychotic drugs: data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST)Anna-Theresa Schulze0Timo Schurr1https://orcid.org/0000-0002-6757-7862Fabienne Post2https://orcid.org/0000-0002-3027-5473Beatrice Frajo-Apor3https://orcid.org/0000-0002-4385-1863Covadonga M. Díaz-Caneja4https://orcid.org/0000-0001-8538-3175Walter Wolfgang Fleischhacker5Michael Davidson6Alex Hofer7https://orcid.org/0000-0002-5834-4258Medical University Innsbruck, Department of Psychiatry, Psychotherapy, Psychosomatics and Medical Psychology, Division of Psychiatry I, Innsbruck, AustriaMedical University Innsbruck, Department of Psychiatry, Psychotherapy, Psychosomatics and Medical Psychology, Division of Psychiatry I, Innsbruck, AustriaMedical University Innsbruck, Department of Psychiatry, Psychotherapy, Psychosomatics and Medical Psychology, Division of Psychiatry I, Innsbruck, AustriaMedical University Innsbruck, Department of Psychiatry, Psychotherapy, Psychosomatics and Medical Psychology, Division of Psychiatry I, Innsbruck, AustriaDepartment of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañlón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), CIBERSAM, ISCIII, School of Medicine, Universidad Complutense, Madrid, Spain.Medical University Innsbruck, Department of Psychiatry, Psychotherapy, Psychosomatics and Medical Psychology, Division of Psychiatry I, Innsbruck, AustriaDepartment of Psychiatry, Nicosia University School of Medicine, CyprusMedical University Innsbruck, Department of Psychiatry, Psychotherapy, Psychosomatics and Medical Psychology, Division of Psychiatry I, Innsbruck, Austriahttps://www.cambridge.org/core/product/identifier/S0924933825100862/type/journal_articleearly-phase schizophreniasubjective well-beinglong-acting injectable antipsychoticspersonal recovery
spellingShingle Anna-Theresa Schulze
Timo Schurr
Fabienne Post
Beatrice Frajo-Apor
Covadonga M. Díaz-Caneja
Walter Wolfgang Fleischhacker
Michael Davidson
Alex Hofer
Subjective well-being in early-phase schizophrenia patients using long-acting injectable vs. oral antipsychotic drugs: data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST)
European Psychiatry
early-phase schizophrenia
subjective well-being
long-acting injectable antipsychotics
personal recovery
title Subjective well-being in early-phase schizophrenia patients using long-acting injectable vs. oral antipsychotic drugs: data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST)
title_full Subjective well-being in early-phase schizophrenia patients using long-acting injectable vs. oral antipsychotic drugs: data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST)
title_fullStr Subjective well-being in early-phase schizophrenia patients using long-acting injectable vs. oral antipsychotic drugs: data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST)
title_full_unstemmed Subjective well-being in early-phase schizophrenia patients using long-acting injectable vs. oral antipsychotic drugs: data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST)
title_short Subjective well-being in early-phase schizophrenia patients using long-acting injectable vs. oral antipsychotic drugs: data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST)
title_sort subjective well being in early phase schizophrenia patients using long acting injectable vs oral antipsychotic drugs data from the european long acting antipsychotics in schizophrenia trial eulast
topic early-phase schizophrenia
subjective well-being
long-acting injectable antipsychotics
personal recovery
url https://www.cambridge.org/core/product/identifier/S0924933825100862/type/journal_article
work_keys_str_mv AT annatheresaschulze subjectivewellbeinginearlyphaseschizophreniapatientsusinglongactinginjectablevsoralantipsychoticdrugsdatafromtheeuropeanlongactingantipsychoticsinschizophreniatrialeulast
AT timoschurr subjectivewellbeinginearlyphaseschizophreniapatientsusinglongactinginjectablevsoralantipsychoticdrugsdatafromtheeuropeanlongactingantipsychoticsinschizophreniatrialeulast
AT fabiennepost subjectivewellbeinginearlyphaseschizophreniapatientsusinglongactinginjectablevsoralantipsychoticdrugsdatafromtheeuropeanlongactingantipsychoticsinschizophreniatrialeulast
AT beatricefrajoapor subjectivewellbeinginearlyphaseschizophreniapatientsusinglongactinginjectablevsoralantipsychoticdrugsdatafromtheeuropeanlongactingantipsychoticsinschizophreniatrialeulast
AT covadongamdiazcaneja subjectivewellbeinginearlyphaseschizophreniapatientsusinglongactinginjectablevsoralantipsychoticdrugsdatafromtheeuropeanlongactingantipsychoticsinschizophreniatrialeulast
AT walterwolfgangfleischhacker subjectivewellbeinginearlyphaseschizophreniapatientsusinglongactinginjectablevsoralantipsychoticdrugsdatafromtheeuropeanlongactingantipsychoticsinschizophreniatrialeulast
AT michaeldavidson subjectivewellbeinginearlyphaseschizophreniapatientsusinglongactinginjectablevsoralantipsychoticdrugsdatafromtheeuropeanlongactingantipsychoticsinschizophreniatrialeulast
AT alexhofer subjectivewellbeinginearlyphaseschizophreniapatientsusinglongactinginjectablevsoralantipsychoticdrugsdatafromtheeuropeanlongactingantipsychoticsinschizophreniatrialeulast